Print Page  Close Window


SEC Filings

8-K
OREXIGEN THERAPEUTICS, INC. filed this Form 8-K on 04/02/2019
Entire Document
 


Case 18-10518-KG     Doc 1006     Filed 03/29/19     Page 2 of 11

UNITED STATES BANKRUPTCY COURT

FOR THE DISTRICT OF DELAWARE

 

In re: Orexigen Therapeutics, Inc.

   Case No. 18-10518 (KG)

Debtor

   Reporting Period: February 1, 2019 - February 28, 2019

 

CERTIFICATION REGARDING POST-PETITION BANK ACCOUNT

RECONCILIATIONS, CASH DISBURSEMENT JOURNALS AND

COMPLIANCE AND PAYMENT OF POST-PETITION TAXES

I, Thomas Lynch, Chief Administrative Officer & General Counsel, of Orexigen Therapeutics, Inc. (the “Debtor”) hereby certify the following:

1. Attached to MOR-1 is a listing of the Debtor’s bank accounts, by account number, and the opening and closing balances. These accounts are reconciled monthly in accordance with the Debtor’s ordinary course accounting practices and are available to the United States Trustee upon request.

2. Cash disbursement journals are maintained in accordance with the Debtor’s ordinary course accounting practices and are available to the United States Trustee upon request.

3. To the best of my knowledge and belief, the Debtor is current on all post-petition taxes, and no post-petition tax amounts are past due.

 

/s/ Thomas Lynch     29 MARCH 2019
Thomas Lynch    

 

Date

Chief Administrative Officer & General Counsel